However, Naito et al. demonstrated, in a retrospective multicenter cohort study, that SEMA4A-positive non-small-cell lung cancers responded significantly better to anti-programmed cell death 1 (PD-1) antibody compared to SEMA4A-negative cells. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.